The correlation of FKN with PD‐L1 tumor expression was also confirmed, as PD‐L1 is a clinically‐approved biomarker of response to PD‐L1/PD‐1 blockade (Doroshow et al, 2021) (Fig EV5B). This evidence concerns the gene CX3CL1 and neoplasm.